Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma

Shane C. McAllister, Klaus Früh, Ashlee V. Moses

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.

Original languageEnglish (US)
Pages (from-to)235-244
Number of pages10
JournalPharmacogenomics
Volume6
Issue number3
DOIs
StatePublished - Apr 1 2005

Keywords

  • Gleevec®
  • HHV-8
  • HO-1
  • KSHV
  • Kaposi's sarcoma
  • Mesoporphyrins
  • c-Kit

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma'. Together they form a unique fingerprint.

  • Cite this